^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
vorbipiprant (CR6086)
i
Other names: CR6086
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Rottapharm Biotech
Drug class:
PGE4 antagonist
Related drugs:
13d
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (clinicaltrials.gov)
P2, N=197, Recruiting, Gruppo Oncologico del Nord-Ovest | N=140 --> 197
Enrollment change
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • POLD1 (DNA Polymerase Delta 1)
|
HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • MET amplification • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
|
Opdivo (nivolumab) • Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181) • vorbipiprant (CR6086)
5ms
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers (clinicaltrials.gov)
P1/2, N=107, Active, not recruiting, Rottapharm Biotech | Recruiting --> Active, not recruiting
Enrollment closed • Mismatch repair • pMMR
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type • RAS mutation
|
balstilimab (AGEN2034) • vorbipiprant (CR6086)
10ms
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers (clinicaltrials.gov)
P1/2, N=107, Recruiting, Rottapharm Biotech | N=55 --> 107 | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
Enrollment change • Trial completion date • Trial primary completion date • Mismatch repair • pMMR
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type • RAS mutation
|
balstilimab (AGEN2034) • vorbipiprant (CR6086)
over1year
CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers (clinicaltrials.gov)
P1/2, N=55, Recruiting, Rottapharm Biotech | Active, not recruiting --> Recruiting | N=28 --> 55 | Trial completion date: Dec 2024 --> Sep 2026 | Trial primary completion date: Oct 2023 --> Mar 2025
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • Metastases
|
BRAF (B-raf proto-oncogene)
|
balstilimab (AGEN2034) • vorbipiprant (CR6086)
almost3years
A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients (clinicaltrials.gov)
P1/2, N=28, Active, not recruiting, Rottapharm Biotech | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Oct 2023
Enrollment closed • Trial primary completion date • Combination therapy • Mismatch repair • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type • RAS mutation
|
balstilimab (AGEN2034) • vorbipiprant (CR6086)
4years
A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients (clinicaltrials.gov)
P1/2, N=27, Recruiting, Rottapharm Biotech
New P1/2 trial • Combination therapy • Mismatch repair
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
balstilimab (AGEN2034) • vorbipiprant (CR6086)
Share via
